Loading
Arrowhead Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Mar 2024.
Arrowhead Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Arrowhead Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Pasadena, United States. It was founded in 1989. In the past year (18 October 2025 to 18 October 2026), 57 filings came from 14 insiders.
There is no open-market purchase to report; the filings show 40 sales worth €24.2M by 9 insiders. Anzalone Christopher Richard filed the largest sale, €5.9M, on 16 December 2025.
With 57 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Our records for Arrowhead Pharmaceuticals, Inc. go back to 2016, with 1 purchase and 113 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 30 September 2025 lists revenue at 829.4 m USD and net income at -1.6 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
195
Thresholds
n/a
Buy Volume
€25,261
1 ops. · all time
Sell Volume
€45M
113 ops. · all time
Who traded when
BuySaleChristopher Richard Anzalone25 sales
James C. Hamilton9 sales
Adeoye Y. Olukotun6 sales
Myszkowski Kenneth Allen4 sales
Victoria Vakiener4 sales
Waddill William D.4 sales
+6 other insiders
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 20 August 2026
Declarations195 total
2,000 shares@ US$86.960.010% mcap7.2% of flowCommon StockSEC:0001242615-26-000002:0
11,600 shares@ US$87.300.061% mcap33.8% of flowCommon StockSEC:0001250379-26-000002:0
11,600 shares@ US$87.25620.011% mcap100.0% of flowCommonSEC144:0001628280-26-057767
2,000 shares@ US$86.93820.0018% mcap100.0% of flowCommonSEC144:0001628280-26-057774
11,882 sharesCommon StockSEC:0002141314-26-000004:0
3,208 shares@ US$70.110.0095% mcap100.0% of flowCommon StockSEC:0000879407-26-000039:0
10,000 shares@ US$75.000.032% mcap13.5% of flowCommon StockSEC:0001830755-26-000007:0
10,000 shares@ US$64.1911.6% of flowCommon StockSEC:0001830755-26-000006:0
75,000 shares0Common StockSEC:0002081169-26-000002:0
75,000 shares0Common StockSEC:0001830755-26-000004:0
540 shares0Common StockSEC:0001627183-26-000003:0
560 shares0Common StockSEC:0001627183-26-000001:0
4,625 shares@ US$61.240.012% mcap5.1% of flowCommon StockSEC:0001830755-26-000002:0
7,416 shares@ US$65.880.021% mcap1.5% of flowCommon StockSEC:0001423029-26-000001:0
16,545 shares@ US$68.693.5% of flowCommon StockSEC:0001423029-25-000009:3
16,545 shares@ US$6.150.3% of flowCommon StockSEC:0001423029-25-000009:1
35,181 shares@ US$69.337.6% of flowCommon StockSEC:0001423029-25-000009:2
7,530 shares@ US$70.0023.6% of flowCommon StockSEC:0001506045-25-000007:0
35,181 shares@ US$6.150.0091% mcap0.7% of flowCommon StockSEC:0001423029-25-000009:0
3,979 shares@ US$66.670.011% mcap0.8% of flowCommon StockSEC:0001423029-25-000007:0
3,090 shares@ US$66.700.0087% mcap8.4% of flowCommon StockSEC:0001242615-25-000006:0
2,799 shares@ US$66.630.0079% mcap9.2% of flowCommon StockSEC:0001826263-25-000006:0
6,083 shares@ US$68.0416.9% of flowCommon StockSEC:0001242615-25-000006:1
10,012 shares@ US$68.332.1% of flowCommon StockSEC:0001423029-25-000007:3
25 of 195 declarations
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a United States-based biopharmaceutical company focused on RNA interference (RNAi) therapeutics, a gene-silencing approach designed to shut down disease-causing proteins at the source. The company is headquartered in Pasadena, California, with major research and development operations in Madison, Wisconsin and San Diego, California, plus chemistry and manufacturing capabilities in Verona, Wisconsin. Founded in May 2003, Arrowhead has spent more than two decades building scientific capabilities around RNAi delivery and target selection, now centered on its proprietary TRiM™ platform.
From an industry standpoint, Arrowhead sits in the specialized precision-medicine segment of healthcare, with a business model that combines platform innovation, internal pipeline development, and an emerging commercial footprint. Its strategy is to apply RNAi across multiple disease areas rather than rely on a single therapeutic niche. Management describes TRiM™ as tissue-agnostic, enabling the company to pursue cardiometabolic, liver, pulmonary, neurological and other hard-to-treat conditions. That breadth is a competitive strength because it creates multiple shots on goal, although the company still faces the usual biotech challenges of clinical execution, regulatory approval and commercialization.
Read moreShow less
A major recent milestone is the FDA approval of REDEMPLO® (plozasiran) in November 2025 for adults with familial chylomicronemia syndrome (FCS), a rare and severe disorder characterized by extremely elevated triglycerides and a high risk of pancreatitis. In December 2025, plozasiran also received FDA Breakthrough Therapy designation in severe hypertriglyceridemia, and in 2026 Arrowhead announced a positive CHMP opinion in Europe. These developments are important because they validate the platform clinically and move Arrowhead from a pure development story toward a company with its first marketed asset and the possibility of broader international expansion.
Beyond plozasiran, Arrowhead continues to advance a pipeline of RNAi candidates in obesity and other cardiometabolic indications, as well as programs that explore newer delivery systems and potential central nervous system applications. The company’s competitive position is therefore based less on scale than on scientific differentiation, delivery technology and the ability to convert platform assets into approvable medicines. For investors in French-speaking markets, Arrowhead represents a high-upside, high-risk U.S. NASDAQ-listed biotech with meaningful pipeline optionality, a first commercial product, and a clear focus on gene-silencing therapeutics.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
